Uterine Artery Embolisation for Symptomatic Adenomyosis with Polyzene F-Coated Hydrogel Microspheres: Three-Year Clinical Follow-Up Using UFS–QoL Questionnaire

R J Nijenhuis, Robbert J. Nijenhuis, Nijenhuis RJ, Smeets AJ, A J Smeets, Albert J. Smeets, Morpurgo M, M Morpurgo, Peter F. Boekkooi, Boekkooi PF, P F Boekkooi, Reuwer PJ, Paul Reuwer, P J H M Reuwer, M Smink, Marieke Smink, Smink M, van Rooij WJ, W J van Rooij, Lohle PN, P. N. M. Lohle, Paul N.M. Lohle
Cardiovascular and interventional radiology · 2014 · vol. 38(1) , pp. 65–71 · doi:10.1007/s00270-014-0878-1 · PMID:24692030 · W2091602854
article OA: closed CC0 ⤵ 32 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-21 ⓘ

Uterine artery embolisation with polyzene F-coated hydrogel microspheres effectively treated symptomatic adenomyosis, with 76% of patients becoming asymptomatic at a mean 37-month follow-up.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-21 · read from full text ⓘ

This study evaluated midterm (mean follow-up 37 months) clinical outcomes of uterine artery embolisation (UAE) for therapy-resistant adenomyosis in 29 consecutive women treated with polyzene F–coated hydrogel microspheres, with junction zone thickness assessed by MRI at baseline and 3 months and symptom/quality of life measured using the UFS–QoL questionnaire at baseline, 3 months, and final follow-up. Symptom severity scores dropped from a mean of 67 at baseline to a mean of 22 at 3 months and to a mean of 15 at final follow-up, with 22/29 (76%) patients asymptomatic and uterine preservation reported in 28/29 (97%); 3 asymptomatic patients required a second UAE and 1 of the remaining symptomatic patients underwent hysterectomy. Outcomes did not differ between pure adenomyosis and adenomyosis with additional fibroids, while baseline junction zone thickness was related to additional therapy. This paper is centrally about endometriosis and/or adenomyosis — it is centrally about adenomyosis treated with uterine artery embolisation and reports symptom and junction zone outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PurposeThis study was designed to assess midterm outcome of uterine artery embolisation (UAE) for women with therapy-resistant adenomyosis using polyzene F-coated hydrogel microspheres.MethodsBetween September 2006 and January 2010, 29 consecutive women with adenomyosis (15 in combination with fibroids) were treated with UAE using polyzene F-coated hydrogel microspheres. Junction zone thickness was assessed with MRI at baseline and 3 months. Women filled out the uterine fibroid symptom and quality of life questionnaire at baseline, 3 months and after a mean clinical follow-up of 37 months (median 35, range 29-64 months).ResultsAt baseline, symptom severity score of 29 women was mean 67 (median 72, range 23-100). At 3 months, this score decreased to mean 22 (median 15, range 0-66) and mean 15 (median 17, range 0-34) at final follow-up. At final follow-up of mean 37 months (median 35, range 29-64 months), 22 of 29 (76 %) patients were asymptomatic. Of these 22 women, 3 underwent a second UAE at 6, 7, and 14 months. The remaining seven patients clinically improved but still had symptoms; one underwent a hysterectomy. There was no difference in outcome between women with pure adenomyosis and women with additional fibroids. The junction zone of 4 women with additional therapy was significantly thicker compared with the remaining 25 patients.ConclusionsIn women with therapy resistant adenomyosis, UAE using polyzene F-coated hydrogel microspheres resulted in 3 years preservation of the uterus in 28 of 29 (97 %) with good clinical outcome in the vast majority of patients. Initial thickness of the junction zone is related to additional therapy.
Full text 7,392 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Purpose This study was designed to assess midterm outcome of uterine artery embolisation (UAE) for women with therapy-resistant adenomyosis using polyzene F-coated hydrogel microspheres.

Methods

Between September 2006 and January 2010, 29 consecutive women with adenomyosis (15 in combination with fibroids) were treated with UAE using polyzene F-coated hydrogel microspheres. Junction zone thickness was assessed with MRI at baseline and 3 months. Women filled out the uterine fibroid symptom and quality of life questionnaire at baseline, 3 months and after a mean clinical follow-up of 37 months (median 35, range 29–64 months).

Results

At baseline, symptom severity score of 29 women was mean 67 (median 72, range 23–100). At 3 months, this score decreased to mean 22 (median 15, range 0–66) and mean 15 (median 17, range 0–34) at final follow-up. At final follow-up of mean 37 months (median 35, range 29–64 months), 22 of 29 (76 %) patients were asymptomatic. Of these 22 women, 3 underwent a second UAE at 6, 7, and 14 months. The remaining seven patients clinically improved but still had symptoms; one underwent a hysterectomy. There was no difference in outcome between women with pure adenomyosis and women with additional fibroids. The junction zone of 4 women with additional therapy was significantly thicker compared with the remaining 25 patients.

Conclusions

In women with therapy resistant adenomyosis, UAE using polyzene F-coated hydrogel microspheres resulted in 3 years preservation of the uterus in 28 of 29 (97 %) with good clinical outcome in the vast majority of patients. Initial thickness of the junction zone is related to additional therapy. Similar content being viewed by others

References

Azzir R (1989) Adenomyosis: current perspectives. Obstet Gynecol Clin N Am 16:221–235 Wood C (1998) Surgical and medical treatment of adenomyosis. Hum Reprod Update 4:323–336 Goodwin SC, McLucas B, Lee M et al (1999) Uterine artery embolization for the treatment of uterine leiomyomata midterm results. J Vasc Interv Radiol 10(9):1159–1165 Smith SJ, Sewall LE, Handelsman A (1999) A clinical failure of uterine fibroid embolization due to adenomyosis. J Vasc Interv Radiol 10(9):1171–1174 Siskin GP, Tubulin ME, Stainken BF, Dowling K, Dolen EG (2001) Uterine artery embolisation for the treatment of adenomyosis: clinical response and evaluation with MR imaging. AJR Am J Roentgenol 177:297–302 Pelage JP, Jacob D, Fazel A et al (2005) Midterm results of uterine artery embolisation for symptomatic adenomyosis: initial experience. Radiology 234:948–953 Lohle PN, De Vries J, Klazen CA et al (2007) Uterine artery embolization for symptomatic adenomyosis with or without uterine leiomyomas with the use of calibrated tris-acryl gelatin microspheres: midterm clinical and MR imaging follow-up. J Vasc Interv Radiol 18(7):835–841 Stampfl S, Bellemann N, Stampfl U et al (2009) Arterial distribution characteristics of Embozene particles and comparison with other spherical embolic agents in the porcine acute embolisation model. J Vasc Interv Radiol 20(12):1597–1607 Harding G, Coyne KS, Thompson CL, Spies JB (2008) The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS–QOL). Health Qual Life Outcomes 6:99 Spies JB, Coyne K, Guaou Guaou N et al (2002) The UFS–QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99:290–300 Reinhold C, McCarthy S, Bret PM et al (1996) Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation. Radiology 199(1):151–158 Bazot M, Cortez A, Darai E et al (2001) Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 16(11):2427–2433 Jha RC, Takahama J, Imaoka I et al (2003) Adenomyosis: MRI of the uterus treated with uterine artery embolisation. AJR Am J Roentgenol 181:851–856 Kitamura Y, Allison SJ, Jha RC et al (2006) MRI of adenomyosis: changes with uterine artery embolisation. AJR Am J Roentgenol 186:855–864 Spies J, Niedzwiecki G, Goodwin S et al (2001) Training standards for physicians performing uterine artery embolisation for leiomyomata: consensus statement developed by the Task Force on Uterine Artery Embolisation and the standards division of the Society of Cardiovascular and Interventional Radiology. J Vasc Interv Radiol 12(1):19–21 Worthington-Kirsch R, Spies JB, Myers ER et al (2005) The Fibroid Registry for outcomes data (FIBROID) for uterine embolisation: short-term outcomes. Obstet Gynecol 106(1):52–59. Erratum in: Obstet Gynecol 106(4):869 Goodwin SC, Spies JB (2009) Uterine fibroid embolisation. N Engl J Med 361(7):690–697 Froeling V, Scheurig-Muenkler C, Hamm B et al (2012) Uterine artery embolisation to treat uterine adenomyosis with or without leiomyomata: results of symptom control and health related quality of life 40 months after treatment. Cardiovasc Interv Radiol 35:523–529 Smeets AJ, Nijenhuis RJ, van Rooij WJ et al (2010) Embolization of uterine leiomyomas with polyzene F-coated hydrogel microspheres: initial experience. J Vasc Interv Radiol 21(12):1830–1834 Chua GC, Wilsher M, Young MP et al (2005) Comparison of particle penetration with non-spherical polyvinyl alcohol versus trisacryl gelatin microspheres in women undergoing premyomectomy uterine artery embolization. Clin Radiol 60(1):116–122 Smeets AJ, Nijenhuis RJ, Boekkooi PF et al (2012) Long-term follow-up of uterine artery embolisation for symptomatic adenomyosis. Cardiovasc Interv Radiol 35:815–819 Sluzewski M, van Rooij WJ, Lohle PN et al (2013) Embolization of meningiomas: comparison of safety between calibrated microspheres and polyvinyl-alcohol particles as embolic agents. AJNR 34(4):727–729 Kim MD, Kim S, Kim NK et al (2006) Long-term results of uterine artery embolisation for symptomatic adenomyosis. AJR Am J Roentgenol 186:855–864 Froeling V, Scheurig-Muenkler C, Hamm B et al (2012) Uterine artery embolisation to treat uterine adenomyosis with or without uterine leiomyomata: results of symptom control and health-related quality of life 40 months after treatment. Cardiovasc Interv Radiol 35(3):523–529 Popovic M, Puchner S, Berzaczy D, Lammer J, Bucek RA (2011) Uterine artery embolisation for the treatment of adenomyosis: a review. J Vasc Interv Radiol 22:901–909 Dutton S, Hirst A, McPherson K, Nicholson T, Maresh MA (2007) A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy. BJOG 114:1340–1351 Conflict of interest Nijenhuis, Smeets, Morpurgo, Boekkooi, Reuwer, Smink, and van Rooij has no conflict of interest. Lohle Consultant for Celonova Bio Sciences, San Antonio, TX. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Nijenhuis, R.J., Smeets, A.J., Morpurgo, M. et al. Uterine Artery Embolisation for Symptomatic Adenomyosis with Polyzene F-Coated Hydrogel Microspheres: Three-Year Clinical Follow-Up Using UFS–QoL Questionnaire. Cardiovasc Intervent Radiol 38, 65–71 (2015). https://doi.org/10.1007/s00270-014-0878-1 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00270-014-0878-1

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Quality of Life Surveys and Questionnaires Uterine Artery Embolization Adenomyosis Adult Female Follow-Up Studies Humans Hydrogel, Polyethylene Glycol Dimethacrylate Hydrogel, Polyethylene Glycol Dimethacrylate Microspheres Middle Aged Prospective Studies Treatment Outcome Uterine Artery Embolization

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (34)

Source provenance

europepmc
last seen: 2026-08-01T06:07:04.264727+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:35.150238+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK